X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2019 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare ASTRAZENECA PHARMA with ALEMBIC PHARMA - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

ASTRAZENECA PHARMA vs ALEMBIC PHARMA - Comparison Results

ASTRAZENECA PHARMA     Change

AstraZeneca Pharma India Limited (APIL) is a 90% subsidiary of the UK based AstraZeneca Pharmaceuticals, which is one of the world's leading pharma companies. APIL has interests in the six crucial areas of cardiovascular, respiratory, maternal health... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    ASTRAZENECA PHARMA ALEMBIC PHARMA ASTRAZENECA PHARMA/
ALEMBIC PHARMA
 
P/E (TTM) x 62.8 15.1 416.4% View Chart
P/BV x 17.7 3.5 509.6% View Chart
Dividend Yield % 0.0 1.1 -  

Financials

 ASTRAZENECA PHARMA   ALEMBIC PHARMA
EQUITY SHARE DATA
    ASTRAZENECA PHARMA
Mar-18
ALEMBIC PHARMA
Mar-19
ASTRAZENECA PHARMA/
ALEMBIC PHARMA
5-Yr Chart
Click to enlarge
High Rs1,278664 192.5%   
Low Rs883412 214.0%   
Sales per share (Unadj.) Rs228.4208.7 109.4%  
Earnings per share (Unadj.) Rs10.431.0 33.4%  
Cash flow per share (Unadj.) Rs16.337.1 43.8%  
Dividends per share (Unadj.) Rs05.50 0.0%  
Dividend yield (eoy) %01.0 0.0%  
Book value per share (Unadj.) Rs98.8144.2 68.5%  
Shares outstanding (eoy) m25.00188.52 13.3%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x4.72.6 183.4%   
Avg P/E ratio x104.217.4 600.3%  
P/CF ratio (eoy) x66.414.5 458.1%  
Price / Book Value ratio x10.93.7 293.1%  
Dividend payout %017.7 0.0%   
Avg Mkt Cap Rs m27,008101,461 26.6%   
No. of employees `0001.4NA-   
Total wages/salary Rs m1,5357,467 20.6%   
Avg. sales/employee Rs Th4,210.9NM-  
Avg. wages/employee Rs Th1,132.2NM-  
Avg. net profit/employee Rs Th191.1NM-  
INCOME DATA
Net Sales Rs m5,71039,347 14.5%  
Other income Rs m12394 130.6%   
Total revenues Rs m5,83339,441 14.8%   
Gross profit Rs m4638,736 5.3%  
Depreciation Rs m1471,152 12.8%   
Interest Rs m0184 0.0%   
Profit before tax Rs m4387,493 5.8%   
Minority Interest Rs m011 0.0%   
Prior Period Items Rs m0-93 0.0%   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m1791,568 11.4%   
Profit after tax Rs m2595,844 4.4%  
Gross profit margin %8.122.2 36.5%  
Effective tax rate %40.820.9 195.3%   
Net profit margin %4.514.9 30.6%  
BALANCE SHEET DATA
Current assets Rs m3,20919,577 16.4%   
Current liabilities Rs m2,07014,896 13.9%   
Net working cap to sales %20.011.9 167.8%  
Current ratio x1.61.3 118.0%  
Inventory Days Days7290 80.6%  
Debtors Days Days3545 77.0%  
Net fixed assets Rs m79027,097 2.9%   
Share capital Rs m50377 13.3%   
"Free" reserves Rs m2,41926,811 9.0%   
Net worth Rs m2,46927,188 9.1%   
Long term debt Rs m04,993 0.0%   
Total assets Rs m4,60547,778 9.6%  
Interest coverage xNM41.7-  
Debt to equity ratio x00.2 0.0%  
Sales to assets ratio x1.20.8 150.6%   
Return on assets %5.612.6 44.6%  
Return on equity %10.521.5 48.8%  
Return on capital %17.723.6 75.2%  
Exports to sales %00-   
Imports to sales %00-   
Exports (fob) Rs mNANA-   
Imports (cif) Rs mNANA-   
Fx inflow Rs m30019,453 1.5%   
Fx outflow Rs m2,0156,065 33.2%   
Net fx Rs m-1,71513,388 -12.8%   
CASH FLOW
From Operations Rs m888,120 1.1%  
From Investments Rs m-94-7,556 1.2%  
From Financial Activity Rs mNA590 0.0%  
Net Cashflow Rs m-61,153 -0.5%  

Share Holding

Indian Promoters % 0.0 74.1 -  
Foreign collaborators % 75.0 0.0 -  
Indian inst/Mut Fund % 0.3 2.9 10.3%  
FIIs % 15.7 9.1 172.5%  
ADR/GDR % 0.0 0.0 -  
Free float % 9.1 13.9 65.5%  
Shareholders   12,856 49,328 26.1%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare ASTRAZENECA PHARMA With:   VENUS REMEDIES  SHASUN PHARMA  PFIZER  TTK HEALTHCARE  ORCHID PHARMA LTD  

Compare ASTRAZENECA PHARMA With:   ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  MYLAN (US)  TEVA PHARMA (Israel)  



Today's Market

Of Falling Stocks, Tumbling Rupee and Weakening Economy(Podcast)

Another week of slowdown in the markets over fears of a looming slowdown in the domestic and global economy continue.

Related Views on News

ALEMBIC PHARMA Announces Quarterly Results (1QFY20); Net Profit Up 36.4% (Quarterly Result Update)

Aug 21, 2019 | Updated on Aug 21, 2019

For the quarter ended June 2019, ALEMBIC PHARMA has posted a net profit of Rs 1 bn (up 36.4% YoY). Sales on the other hand came in at Rs 9 bn (up 10.0% YoY). Read on for a complete analysis of ALEMBIC PHARMA's quarterly results.

ASTRAZENECA PHARMA Announces Quarterly Results (1QFY20); Net Profit Up 236.5% (Quarterly Result Update)

Aug 8, 2019 | Updated on Aug 8, 2019

For the quarter ended June 2019, ASTRAZENECA PHARMA has posted a net profit of Rs 215 m (up 236.5% YoY). Sales on the other hand came in at Rs 2 bn (up 26.7% YoY). Read on for a complete analysis of ASTRAZENECA PHARMA's quarterly results.

ALEMBIC PHARMA 2018-19 Annual Report Analysis (Annual Result Update)

Jun 13, 2019 | Updated on Jun 13, 2019

Here's an analysis of the annual report of ALEMBIC PHARMA for 2018-19. It includes a full income statement, balance sheet and cash flow analysis of ALEMBIC PHARMA. Also includes updates on the valuation of ALEMBIC PHARMA.

ASTRAZENECA PHARMA Announces Quarterly Results (4QFY19); Net Profit Up 204.9% (Quarterly Result Update)

May 27, 2019 | Updated on May 27, 2019

For the quarter ended March 2019, ASTRAZENECA PHARMA has posted a net profit of Rs 98 m (up 204.9% YoY). Sales on the other hand came in at Rs 2 bn (up 26.3% YoY). Read on for a complete analysis of ASTRAZENECA PHARMA's quarterly results.

ALEMBIC PHARMA Announces Quarterly Results (4QFY19); Net Profit Up 28.9% (Quarterly Result Update)

May 9, 2019 | Updated on May 9, 2019

For the quarter ended March 2019, ALEMBIC PHARMA has posted a net profit of Rs 1 bn (up 28.9% YoY). Sales on the other hand came in at Rs 9 bn (up 8.6% YoY). Read on for a complete analysis of ALEMBIC PHARMA's quarterly results.

More Views on News

Most Popular

This 60-Year Old Smallcap Company Could Be Our Next Recommendation(The 5 Minute Wrapup)

Aug 12, 2019

My experience at the recent AGM of this smallcap company which has financials of any FMCG major.

Interest Rates Are Low. Buy Solid Dividend Stocks Instead(The 5 Minute Wrapup)

Aug 13, 2019

The dividends paid by these stocks are helpful when interest rates are falling.

My Top 3 Dividend Stocks to Buy Now(Profit Hunter)

Aug 19, 2019

As markets continue to rattle amid earning season, upcoming elections, volatile crude price and US China trade war, it's a great idea to add some stability to your portfolio by adding dividend stocks.

Smallcaps that Will Outperform in the Market Rebound(Profit Hunter)

Aug 12, 2019

Only These Smallcaps Will Give Historic Returns in the Future.

One Stock You Could Consider Buying Now and Holding Forever(The 5 Minute Wrapup)

Aug 22, 2019

If there is one company that I could recommend that is making the most of the tech disruption, this would be it.

More

Get the Indian Stock Market's
Most Profitable Ideas

How To Beat Sensex Guide 2019
Get our special report, How to Beat Sensex Nearly 3X Now!
We will never sell or rent your email id.
Please read our Terms

ASTRAZENECA PHARMA SHARE PRICE


Aug 23, 2019 (Close)

TRACK ASTRAZENECA PHARMA

  • Track your investment in ASTRAZENECA PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON ASTRAZENECA PHARMA

ASTRAZENECA PHARMA - VENUS REMEDIES COMPARISON

COMPARE ASTRAZENECA PHARMA WITH

MARKET STATS